Abhishek Kavati
Research Subjects
Research Interests
Abhishek Kavati has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Ortiz
Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America
2 shared publications - Abdulaziz Alhossan
Department of Clinical Pharmacy, King Saud University, Riyadh, Saudi Arabia
1 shared publication - Christopher S. Lee
William F. Connell School of Nursing, Boston College, Chestnut Hill, MA 02467, USA
1 shared publication - Ivo Abraham
Center for Health Outcomes and Pharmacoeconomic Research, R. Ken Coit College of Pharmacy, University of Arizona, Tucson
1 shared publication - Jalpa A. Doshi
University of Pennsylvania, Philadelphia, PA
1 shared publication Jordan Jahnke
Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa
1 shared publication
Latest Publications
- Open Access
- 1 February 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (2) , 507-515.e10
Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population
- 1 February 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (2) , 507-515.e10
Open AccessOmalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population
- Open Access
- 14 February 2019
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 15 (5) , 553-569
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018
Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008–2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation. Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing.
- 14 February 2019
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 15 (5) , 553-569
Open AccessShort- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018
Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008–2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation. Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing.